[{"id":"9678854b-d3b2-42be-bf3d-1cdfa6e7652f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05557877","created_at":"2024-04-24T19:42:10.923Z","updated_at":"2025-02-25T17:38:07.530Z","phase":"Phase 2","brief_title":"Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer","source_id_and_acronym":"NCT05557877","lead_sponsor":"Mayo Clinic","biomarkers":" ER • CRP","pipe":"","alterations":" ","tags":["ER • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/09/2023","start_date":" 03/09/2023","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2027","study_completion_date":" 01/30/2027","last_update_posted":"2025-01-28"},{"id":"23dbdc8e-972e-4762-87c9-f40d67d274d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05080946","created_at":"2021-10-18T12:53:00.791Z","updated_at":"2024-07-02T16:34:26.049Z","phase":"Phase 1","brief_title":"Using Aspirin to Improve Immunological Features of Ovarian Tumors","source_id_and_acronym":"NCT05080946","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD163 • FOXP3","pipe":"","alterations":" ","tags":["CD163 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/02/2021","start_date":" 11/02/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-14"},{"id":"4ffad9ac-b9ad-4a72-be3d-2530bfde2f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03480776","created_at":"2021-01-18T17:09:00.672Z","updated_at":"2024-07-02T16:35:12.838Z","phase":"Phase 2","brief_title":"ASA in Prevention of Ovarian Cancer (STICs and STONEs)","source_id_and_acronym":"NCT03480776","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 07/24/2018","start_date":" 07/24/2018","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 09/15/2025","study_completion_date":" 09/15/2025","last_update_posted":"2024-03-26"},{"id":"bc0ab9aa-dfd0-4ac8-8031-f30fc9f954e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05411718","created_at":"2022-06-09T13:55:29.609Z","updated_at":"2024-07-02T16:35:15.093Z","phase":"Phase 2","brief_title":"A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome","source_id_and_acronym":"NCT05411718","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-03-13"},{"id":"b4b2fabf-333a-456a-a058-b135346152b4","acronym":"ALASCCA","url":"https://clinicaltrials.gov/study/NCT02647099","created_at":"2021-01-18T12:52:53.182Z","updated_at":"2024-07-02T16:35:15.603Z","phase":"Phase 3","brief_title":"Adjuvant Low Dose Aspirin in Colorectal Cancer","source_id_and_acronym":"NCT02647099 - ALASCCA","lead_sponsor":"Anna Martling","biomarkers":" PIK3CA • PTEN • PIK3R1","pipe":"","alterations":" ","tags":["PIK3CA • PTEN • PIK3R1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 04/07/2016","start_date":" 04/07/2016","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-03-08"},{"id":"2bdd752e-e61e-42b2-941d-7d28dae7f2cb","acronym":"SAKK 41/13","url":"https://clinicaltrials.gov/study/NCT02467582","created_at":"2021-01-18T11:52:41.622Z","updated_at":"2024-07-02T16:35:23.344Z","phase":"Phase 3","brief_title":"Adjuvant Aspirin Treatment for Colon Cancer Patients","source_id_and_acronym":"NCT02467582 - SAKK 41/13","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 185","initiation":"Initiation: 06/09/2016","start_date":" 06/09/2016","primary_txt":" Primary completion: 09/14/2023","primary_completion_date":" 09/14/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-17"},{"id":"b01abc76-a9b1-4a0e-8d3d-7c94aad01cf8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02804815","created_at":"2021-01-18T13:45:12.829Z","updated_at":"2024-07-02T16:35:27.565Z","phase":"Phase 3","brief_title":"Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours","source_id_and_acronym":"NCT02804815","lead_sponsor":"University College, London","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HER-2 negative • HR negative • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HER-2 negative • HR negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 11000","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-11-30"},{"id":"97d535c2-613d-4bea-bd1b-97d4e14f968f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02965703","created_at":"2021-01-18T14:34:35.708Z","updated_at":"2024-07-02T16:35:31.010Z","phase":"Phase 2","brief_title":"Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma","source_id_and_acronym":"NCT02965703","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BAX","pipe":"","alterations":" ","tags":["BCL2 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 01/16/2018","start_date":" 01/16/2018","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2023-10-31"},{"id":"16375f35-57e8-4891-ab8d-34d2a7ad1e54","acronym":"","url":"https://clinicaltrials.gov/study/NCT04495894","created_at":"2021-01-18T21:35:34.159Z","updated_at":"2024-07-02T16:35:32.024Z","phase":"Phase 1","brief_title":"Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma","source_id_and_acronym":"NCT04495894","lead_sponsor":"Emory University","biomarkers":" IL6 • TNFA • CXCL8 • IL2 • IL10 • CSF2 • IL1A • IL1B","pipe":" | ","alterations":" IL10 elevation","tags":["IL6 • TNFA • CXCL8 • IL2 • IL10 • CSF2 • IL1A • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL10 elevation"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-10-24"},{"id":"cb93f92e-b678-4306-ae62-affa614ff973","acronym":"","url":"https://clinicaltrials.gov/study/NCT02552394","created_at":"2021-01-18T12:21:08.158Z","updated_at":"2024-07-02T16:35:51.280Z","phase":"Phase 1","brief_title":"J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts","source_id_and_acronym":"NCT02552394","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CYP17A1","pipe":"","alterations":" ","tags":["CYP17A1"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 11/14/2019","primary_completion_date":" 11/14/2019","study_txt":" Completion: 01/03/2021","study_completion_date":" 01/03/2021","last_update_posted":"2023-04-06"},{"id":"4d95ba7d-235d-4c76-9c30-eae94461392a","acronym":"AAS-Lynch","url":"https://clinicaltrials.gov/study/NCT02813824","created_at":"2021-01-18T13:48:03.647Z","updated_at":"2024-07-02T16:36:08.238Z","phase":"Phase 3","brief_title":"Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome","source_id_and_acronym":"NCT02813824 - AAS-Lynch","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" MLH1 • MSH6 • MSH2 • PMS2","pipe":"","alterations":" ","tags":["MLH1 • MSH6 • MSH2 • PMS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 852","initiation":"Initiation: 11/14/2017","start_date":" 11/14/2017","primary_txt":" Primary completion: 06/15/2026","primary_completion_date":" 06/15/2026","study_txt":" Completion: 12/15/2027","study_completion_date":" 12/15/2027","last_update_posted":"2022-06-28"},{"id":"b9edba5c-97ab-48e7-9714-b3ab8951ab79","acronym":"MesaCAPP","url":"https://clinicaltrials.gov/study/NCT04920149","created_at":"2021-06-10T01:52:40.134Z","updated_at":"2024-07-02T16:36:14.592Z","phase":"Phase 2","brief_title":"Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome","source_id_and_acronym":"NCT04920149 - MesaCAPP","lead_sponsor":"Ann-Sofie Backman","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 03/21/2022","start_date":" 03/21/2022","primary_txt":" Primary completion: 10/15/2028","primary_completion_date":" 10/15/2028","study_txt":" Completion: 10/15/2038","study_completion_date":" 10/15/2038","last_update_posted":"2022-03-28"},{"id":"c1812af5-f31c-4727-996c-067f0f1f8110","acronym":"","url":"https://clinicaltrials.gov/study/NCT01483144","created_at":"2021-01-18T06:11:45.479Z","updated_at":"2024-07-02T16:36:29.390Z","phase":"Phase 3","brief_title":"Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)","source_id_and_acronym":"NCT01483144","lead_sponsor":"Cancer Prevention Pharmaceuticals, Inc.","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Flynpovi (eflornithine/sulindac)"],"overall_status":"Completed","enrollment":" Enrollment 171","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2021-06-08"},{"id":"6f8ede38-e501-4f64-9cdf-e37b5d5c9b94","acronym":"","url":"https://clinicaltrials.gov/study/NCT02326779","created_at":"2021-01-18T11:02:21.157Z","updated_at":"2024-07-02T16:36:31.162Z","phase":"Phase 3","brief_title":"Low-dose Aspirin Therapy for Esophageal Cancer","source_id_and_acronym":"NCT02326779","lead_sponsor":"Zhejiang University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2021-04-27"},{"id":"7380c081-f953-4211-9a39-e1cfa850f878","acronym":"","url":"https://clinicaltrials.gov/study/NCT02052908","created_at":"2021-03-25T17:20:15.004Z","updated_at":"2024-07-02T16:36:35.655Z","phase":"Phase 1","brief_title":"Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome","source_id_and_acronym":"NCT02052908","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • MLH1 mutation • PMS2 mutation","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MLH1 mutation • PMS2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 01/27/2014","start_date":" 01/27/2014","primary_txt":" Primary completion: 10/25/2019","primary_completion_date":" 10/25/2019","study_txt":" Completion: 01/05/2021","study_completion_date":" 01/05/2021","last_update_posted":"2021-01-25"},{"id":"73552f87-164d-42a3-b749-7eef35e0b7c2","acronym":"ASPIK French","url":"https://clinicaltrials.gov/study/NCT02945033","created_at":"2022-01-05T22:01:00.037Z","updated_at":"2024-07-02T16:36:54.260Z","phase":"Phase 3","brief_title":"Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk","source_id_and_acronym":"NCT02945033 - ASPIK French","lead_sponsor":"University Hospital, Rouen","biomarkers":" PI3K","pipe":"","alterations":" ","tags":["PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 264","initiation":"Initiation: 07/12/2018","start_date":" 07/12/2018","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2019-10-24"},{"id":"932b6758-a290-4d1d-8d85-a12ec556b765","acronym":"","url":"https://clinicaltrials.gov/study/NCT00983580","created_at":"2021-01-18T03:50:19.599Z","updated_at":"2024-07-02T16:36:55.983Z","phase":"Phase 2","brief_title":"Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer","source_id_and_acronym":"NCT00983580","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 08/20/2009","start_date":" 08/20/2009","primary_txt":" Primary completion: 10/07/2016","primary_completion_date":" 10/07/2016","study_txt":" Completion: 08/13/2019","study_completion_date":" 08/13/2019","last_update_posted":"2019-09-04"},{"id":"e236cba8-19db-4ce9-a82b-89167143d80f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03900871","created_at":"2021-02-24T13:02:34.363Z","updated_at":"2024-07-02T16:37:01.002Z","phase":"Phase 1","brief_title":"Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma","source_id_and_acronym":"NCT03900871","lead_sponsor":"Hebei Medical University Fourth Hospital","biomarkers":" PTGS2","pipe":" | ","alterations":" PTGS2 expression","tags":["PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTGS2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 04/10/2019","start_date":" 04/10/2019","primary_txt":" Primary completion: 04/30/2020","primary_completion_date":" 04/30/2020","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2019-04-03"},{"id":"3ce0329b-2881-44da-aa28-7cd3d5304e86","acronym":"","url":"https://clinicaltrials.gov/study/NCT02048735","created_at":"2021-01-18T09:24:49.775Z","updated_at":"2024-07-02T16:37:15.587Z","phase":"Phase 1","brief_title":"Naproxen for Lynch Syndrome","source_id_and_acronym":"NCT02048735","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":"","study_completion_date":"","last_update_posted":"2017-12-12"},{"id":"bb338bc0-84a5-416d-9940-f963dcb3cec6","acronym":"FAST","url":"https://clinicaltrials.gov/study/NCT02611973","created_at":"2021-01-18T12:41:23.906Z","updated_at":"2024-07-02T16:37:19.528Z","phase":"Phase 3","brief_title":"Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia","source_id_and_acronym":"NCT02611973 - FAST","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" JAK2 V617F • CALR mutation","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxyurea • aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 2250","initiation":"Initiation: 03/10/2016","start_date":" 03/10/2016","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2017-07-26"},{"id":"56f85af2-cb22-4a84-8aae-f0ed036e3a5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00468910","created_at":"2021-01-18T01:40:01.650Z","updated_at":"2024-07-02T16:37:21.517Z","phase":"Phase 2","brief_title":"Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer","source_id_and_acronym":"NCT00468910","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Completed","enrollment":" Enrollment 79","initiation":"Initiation: 03/01/2007","start_date":" 03/01/2007","primary_txt":" Primary completion: 12/01/2009","primary_completion_date":" 12/01/2009","study_txt":" Completion: 08/01/2011","study_completion_date":" 08/01/2011","last_update_posted":"2017-05-31"},{"id":"04b616c9-6937-4ad6-ac25-c7e749052a9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00175838","created_at":"2022-04-24T08:54:14.281Z","updated_at":"2024-07-02T16:37:26.468Z","phase":"","brief_title":"Primary Thrombocythaemia 1 Trial","source_id_and_acronym":"NCT00175838","lead_sponsor":"University of Cambridge","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxyurea • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 1398","initiation":"Initiation: 07/01/1997","start_date":" 07/01/1997","primary_txt":" Primary completion: 11/01/2016","primary_completion_date":" 11/01/2016","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2017-01-18"},{"id":"95f6d6f9-21d5-47ce-8696-ca2c222a1a8d","acronym":"CaPP3 Israel","url":"https://clinicaltrials.gov/study/NCT02497820","created_at":"2021-03-25T18:19:44.945Z","updated_at":"2024-07-02T16:37:29.546Z","phase":"Phase 3","brief_title":"Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers","source_id_and_acronym":"NCT02497820 - CaPP3 Israel","lead_sponsor":"Tel-Aviv Sourasky Medical Center","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSI-H/dMMR • MSH6 deletion","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH6 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 1800","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2016-08-25"}]